Idarucizumab for dabigatran reversal in daily clinical practice: A case series
CONCLUSION
Our first experiences with idarucizumab use in daily-care settings support a rapid and efficient decrease in the anticoagulant effect of dabigatran in emergency situations. Late re-occurrence of dabigatran effect was noted in a subset of patients with severe renal failure.
Source: European Journal of Anaesthesiology - Category: Anesthesiology Tags: Coagulation Source Type: research
More News: Anesthesia | Anesthesiology | Bleeding | Cardiology | Emergency Medicine | Heart | Hemorrhagic Stroke | Ischemic Stroke | Laboratory Medicine | Pradaxa | Renal Failure | Septic Shock | Slovenia Health | Stroke